Puma Biotechnology, Inc. - News Releases

Get News Alerts by RSS

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

12/30/2015

Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card

12/29/2015

Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card

12/23/2015

ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card

12/18/2015

Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients

12/16/2015

Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea

12/11/2015

Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) at the 2015 San Antonio Breast Cancer Symposium

12/10/2015

Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium

12/10/2015

Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer

11/30/2015

Puma Biotechnology Provides Update from Meeting with European Medicines Agency

11/13/2015

Puma Biotechnology to Present Data at the San Antonio Breast Cancer Symposium (SABCS)

11/09/2015

Puma Biotechnology Reports Third Quarter 2015 Financial Results

11/03/2015

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

09/26/2015

Puma Biotechnology Announces Presentation of Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients

09/10/2015

Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation

08/10/2015

Puma Biotechnology Reports Second Quarter 2015 Financial Results

06/04/2015

Puma Biotechnology to Present at Goldman Sachs Healthcare Conference

06/01/2015

Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival

05/27/2015

Puma Biotechnology to Present at Jefferies 2015 Healthcare Conference

05/13/2015

Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

05/12/2015

Puma Biotechnology to Participate in Fireside Chat at UBS Global Healthcare Conference

05/11/2015

Puma Biotechnology Reports First Quarter 2015 Financial Results

05/06/2015

Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference

04/30/2015

Puma Biotechnology to Present at Deutsche Bank Health Care Conference

04/14/2015

Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients

03/10/2015

Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer

03/02/2015

Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results

02/24/2015

Puma Biotechnology to Present at Cowen Health Care Conference

02/18/2015

Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare Conference

02/05/2015

Puma Biotechnology to Present at Leerink Global Healthcare Conference

01/27/2015

Puma Biotechnology Closes $218 Million Public Offering of Common Stock

01/22/2015

Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares

01/21/2015

Puma Biotechnology Prices Public Offering of Common Stock

01/20/2015

Puma Biotechnology Announces Proposed Public Offering

01/05/2015

Puma Biotechnology to Present at J.P. Morgan Healthcare Conference